Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Centhaquine - Midwestern University/Pharmazz

Next Previous
Drug Profile

Centhaquine - Midwestern University/Pharmazz

Alternative Names: Centhaquin - Midwestern University/Pharmazz; Centhaquine citrate; Lyfaquin; PMZ 2010; PMZ-2010 citrate

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Midwestern University; Pharmazz
  • Developer Pharmazz
  • Class Analgesics; Antihaemorrhagics; Antihypertensives; Cardiovascular therapies; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypovolaemic shock
  • Phase III Ischaemic stroke
  • Phase II SARS-CoV-2 acute respiratory disease; Septic shock
  • No development reported Acute kidney injury; Heart arrest; Postoperative pain

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for phase-I development in SARS-COV-2 acute respiratory disease in India
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Ischaemic stroke in USA
  • 31 Jul 2024 Phase-II clinical trials in SARS-COV-2 acute respiratory disease in USA (unspecified route) prior to July 2024 (Pharmazz pipeline, July 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top